Author

Darla Quijada

Johns Hopkins UniversityORCID 0000-0002-1706-8074Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

Petros C. KarakousisiD· 3 shared J. David PeskeiD· 2 shared Jennie Ruelas CastilloiD· 2 shared Styliani KaranikaiD· 2 shared Theodoros KarantanosiD· 2 shared Tianyin WangiD· 2 shared Addis Yilma· 1 shared Alannah D. Taylor· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Petros C. KarakousisORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Early tuberculosis treatment remodels blood mRNA and small RNA, and a baseline host signature is associated with early culture conversion

G. V. Anoushka Chinmayi, Darla Quijada, Artur T. L. Queiroz, Neil Alexander Martinson, Bruno B. Andrade, Marc K. Halushka, Joel S. Bader, Petros C. Karakousis

This study identifies blood-based biomarkers that predict early tuberculosis culture conversion by analyzing mRNA and small RNA changes during treatment.

bioRxiv · Oct 27, 2026 · PreprintImmunology

Therapeutic DNA Vaccine Targeting Mycobacterium tuberculosis Persisters Shortens Curative Tuberculosis Treatment

Styliani Karanika, Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, James T. Gordy, Hannah Bailey, Darla Quijada, Kaitlyn Fessler, Rokeya Tasneen, Elisa M. Rouse Salcido, Farah Shamma, Harley T. Harris, Fengyixin Chen, Rowan E. Bates, Heemee Ton, , Petros C. Karakousis

A DNA vaccine targeting Mtb persisters reduces TB treatment duration in mice and elicits similar immune responses in macaques.

Journal of Clinical Investigation · Feb 3, 2026Peer-reviewedImmunology

Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model

Tianyin Wang, Darla Quijada, Taha S. Ahmedna, Jennie Ruelas Castillo, Nour Sabiha Naji, J. David Peske, Petros C. Karakousis, Suman Paul, Theodoros Karantanos, Styliani Karanika

This study shows that targeting CCRL2 with an antibody-drug conjugate improves TB treatment in mice by reducing inflammation and enhancing immune responses.

Frontiers in Immunology · Mar 20, 2025Peer-reviewedImmunology